Ono Pharmaceutical Co (Ono Pharmaceutical Co) Total Liabilities : $702 Mil (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co Total Liabilities?

Ono Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 was $702 Mil.

Ono Pharmaceutical Co's quarterly Total Liabilities increased from Jun. 2023 ($731.69 Mil) to Sep. 2023 ($761.81 Mil) but then declined from Sep. 2023 ($761.81 Mil) to Dec. 2023 ($701.79 Mil).

Ono Pharmaceutical Co's annual Total Liabilities declined from Mar. 2021 ($972.27 Mil) to Mar. 2022 ($653.83 Mil) but then increased from Mar. 2022 ($653.83 Mil) to Mar. 2023 ($1,007.18 Mil).

Ono Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Ono Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ono Pharmaceutical Co Total Liabilities Chart

Ono Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

830.63

979.15

972.27

653.83

1,007.18

Ono Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															765.17	1,007.18	731.69	761.81	701.79

Ono Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ono Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	919.685	+	(49.961	+	12.471
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	25.063)
	=	1,007

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	6601.89	-	5594.71
	=	1,007

Ono Pharmaceutical Co's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	623.052	+	(43.895	+	10.779
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	24.066)
	=	702

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	6193.33	-	5491.539
	=	702

Ono Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

OPHLF:USA 4528:Japan ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines

From GuruFocus

Ono Pharmaceutical Co Stock Appears To Be Modestly Undervalued

By GF Value • 07-05-2021

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

By PRNewswire • 12-01-2023

Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report

By Holly LaFon Holly LaFon • 05-13-2016

T. Rowe Price Japan Fund Purchases 5 Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-18-2017